Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATE: Rosiglitazone Add-on to Metformin in T2DM
NCT00203632Phase 3Terminated
- Sponsor
- University of Calgary
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rosiglitazone + Metformin with Placebo + Metformin (2 arms). Primary endpoint: Percent change in forearm blood flow to acetylcholine. Started Sep 2003; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00203632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203632.